胶质瘤中P170、MGMT、TOPⅡ和GST-π的蛋白表达与化疗药物敏感性的研究

Expression and clinical significance of P170 ,MGMT,TOPH and GST-π in gliomas

目的探讨人脑胶质瘤组织中P170、MGMT、TOPⅡ和GST-π的蛋白表达与临床化疗药物敏感性的关系。方法应用单克隆抗体、免疫组化技术S-P法，对52例低级别（Ⅱ级）和56例高级别（Ⅲ～Ⅳ级）胶质瘤病人组织标本行上述4种指标检测，并分析其术后化疗药物的敏感性。结果胶质瘤组织中P170、MGMT、TOPⅡ和GST-Ⅱ的表达在低级别和高级别胶质瘤之间有统计学意义（P〈0．01），病人术后化疗药物敏感性分析结果显示：大部分P170、TOPⅡ高表达的患者用化疗药物更为有效。结论胶质瘤组织中P170、MGMT、TOPⅡ和GST-Ⅱ的表达高低可指导临床选择化疗药物。

Objective To investigate the expressions of P170, MGMT,TOPⅡ and GST-πin gliomas and evaluate their clinical significance. Method The expressions of P170 ,MGMT,TOPII and GST-πwere tested by S-P immunohistochemical technique using monoclonal antibody to their protein in 52cases of low-grade gliomas（ WHO Ⅱ grade） and 56 cases of high-grade gliomas（ WHO Ⅲ-Ⅳ grade） and anahysed the sensitivity chemotherapy drugs in chinical. Results The expressions of P170,MGMT,TOPⅡ and GST-πin gliomas had significant differences between low-grade and high-grade gliomas （ P 〈 0.01 ）. chemotherapy drugs was choiced respectively. Condusions Combining detection of P170, MGMT,TOPll and GST-π is benefit for the choice of the chemotherapy drugs choicing corrective chemotherapy drugs after operation can reduce mortality of glioma patients.